Pay in 4 interest-free payments of $6.89 Learn more
Ships within 48 hours · Estimated delivery Oct 11 - Oct 16
Exendin-4 treatment enhances L-DOPA evoked release of striatal dopamine and decreases dyskinetic movements in the 6-hydoxydopamine lesioned rat
This 4-week cycle also aligns with the 4-week titration interval, making it straightforward to tie site rotation to your dose escalation calendar
If you notice this effect, switch to morning dosing
Patients experiencing side effects should be encouraged to report them, as their contributions are vital for advancing scientific understanding and improving patient safety for everyone
01 Once-Weekly Semaglutide in Adults with Overweight or Obesity New England Journal of Medicine 2021 peer-reviewed original research (randomized controlled trial) Open source 02 Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity New England Journal of Medicine 2025 peer-reviewed original research (randomized controlled trial) Open source 03 Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes New England Journal of Medicine 2023 peer-reviewed original research (randomized controlled trial) Open source 04 Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes New England Journal of Medicine 2016 peer-reviewed original research (randomized controlled trial) Open source 05 Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes New England Journal of Medicine 2019 peer-reviewed original research (randomized controlled trial) Open source 06 Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis New England Journal of Medicine 2025 peer-reviewed original research (randomized controlled trial, planned interim analysis) Open source 07 Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial Nature Medicine 2024 peer-reviewed original research (secondary/subgroup analysis of RCT) Open source 08 Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review International Journal of Molecular Sciences 2024 systematic literature review Open source Product FAQ Questions buyers ask about Semaglutide What are Semaglutide's reference identity values?+ The commonly cited free-compound reference is CAS 910463-68-2, PubChem CID 56843331, formula CHNO and average molecular weight about 4113.6 Da
